Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Monthly Archives: September 2015

Health and Human Services Secretary Burwell Previews Third Open Enrollment

ObamacareWashington, DC, September 23, 2015 ― In a speech at the Howard University College of Medicine yesterday, U.S. Secretary of Health and Human Services Sylvia M. Burwell reflected on the progress of the first five years of the Affordable Care Act and provided a look at the upcoming Open Enrollment period.

In her speech, the Secretary described how the law is working to deliver access, affordability, and quality coverage and outlined how the Department of Health and Human Services will meet the challenges of the upcoming Open Enrollment for the Health Insurance Marketplaces. Continue reading

FDA Awards 18 Grants to Stimulate Product Development for Rare Diseases

Rare Disease 2Washington, DC, September 22, 2015 ― The U.S. Food and Drug Administration today announced it has awarded 18 new research grants totaling more than $19 million to boost the development of products for patients with rare diseases, which affect the lives of nearly 30 million Americans.

A rare disease, also referred to as an orphan disease, is any diseasethat affects a small percentage of the population. Most rare diseasesare genetic, and thus are present throughout the person’s entire life, even if symptoms do not immediately appear.

These new grants were awarded to principal investigators in ten states, with research spanning clinical sites domestically and internationally. Continue reading

HHS Advances Development of New Monoclonal Antibody Drug for Ebola

Washington, DC, September 22, 2015 ― A novel Ebola virus disease treatment based on three monoclonal antibodies will advance in development through an agreement between the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) and Regeneron Pharmaceuticals, Inc. of Tarrytown, New York.

ASPR’s Biomedical Advanced Research and Development Authority (BARDA) will provide up to a total of $38 million over the next 23 months to support development as well as manufacturing of the experimental monoclonal antibody therapeutic drug for use in studies. Continue reading

PhRMA Member Companies Invested $51.2 Billion in R&D in 2014; Over $600 Billion Since 2000

PhRMA jpgWashington, DC, September 22, 2015 ― Pharmaceutical Research and Manufacturers of America’s (PhRMA) member companies invested an estimated $51.2 billion last year in the research and development (R&D) of new innovative treatments and cures.

The figure represents the majority of all biopharmaceutical R&D spending — both public and private — in the United States.

The new R&D numbers, the result of a recent survey of PhRMA member companies, are highlighted in the PhRMA 2015 Biopharmaceutical Research Industry Profile as well as a new industry chart pack, Biopharmaceuticals in Perspective, which were published in April.

Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures. Continue reading

Medicare Advantage Premiums Remain Stable; Part D to Remain Stable; Enrollment at All-Time High

Medicare 1Washington, DC, September 21, 2015 ― Today, the Centers for Medicare & Medicaid Services (CMS) announced that Medicare Advantage premiums will remain stable and more enrollees will have access to higher quality plans while, for a sixth straight year, enrollment is projected to increase to a new all-time high.

In addition, CMS released today new information that shows that millions of seniors and people with disabilities with Medicare continue to enjoy prescription drug discounts and affordable benefits as a result of the Affordable Care Act.

Today’s announcement comes as CMS releases the premiums and costs for Medicare health and drug plans for the 2016 calendar year.  Continue reading

Rutgers Economic Advisory Service Reports NJ Economy Will Grow Slower than US’s Over Next 10 Years

New Brunswick, NJ, September 21, 2015The Record reported that New Jersey’s economy will continue to grow more slowly than the nation’s through 2025 before keeping pace with the national rate over the next 20 years, according to Nancy Mantell, director of the Rutgers Economic Advisory Service, at R/ECON’s semiannual subscriber conference Friday.

According to Rutgers, job growth in New Jersey will be 1.1 percent this year and next after recording a 0.7 percent gain in 2014, a decline of 17,400 jobs from 2013’s total. Continue reading

PhRMA Publishes Report on Alzheimer’s Research; ‘Setbacks’ Critical for Tomorrow’s Breakthroughs

Alzheimer's puzzleWashington, DC, September 20, 2015 ― The Pharmaceutical Research and Manufacturers of America (PhRMA) in July released a new report, “Researching Alzheimer’s Medicines: Setbacks and Stepping Stones,” that found 123 potential medicines for Alzheimer’s disease were halted in clinical trials between 1998 and 2014, while four medicines were approved during the same timeframe.

While this 30-to-1 ratio of setbacks to successes demonstrates the challenge and complexity of Alzheimer’s research, it is important to recognize the role of these so-called “failures” in advancing knowledge and laying the foundation for future advances. Continue reading

Rutgers and Israel Healthy, Functional, and Medical Foods Alliance Announced

New Brunswick, NJ, September 19, 2015 ― In a ceremony yesterday at Rutgers, The State University of New Jersey, officials of Israel’s Tel-Hai College, Israel’s Economic Development Taskforce, and Rutgers signed a memorandum of understanding to launch the New Jersey-Israel Healthy, Functional, and Medical Foods Alliance.

Christopher J. Molloy, senior vice president for research and economic development at Rutgers, said the university’s wide-ranging research capabilities, faculty expertise, and business incubation leadership offer the alliance a strong foundation for its launch.

“This innovative collaboration is exciting because it promises to further engage Rutgers researchers with some of New Jersey’s most important industry sectors,” Molloy said. “We’re enthusiastic about its potential for having a substantial economic impact.” Continue reading

Event: HINJ to Host 2015 Life Sciences Celebration October 30; Honorees Named

hinj_logo_high_resNew Brunswick, NJ, September 18, 2015 ― The HealthCare Institute of New Jersey (HINJ) will honor meritorious leadership in and contributions to New Jersey’s life sciences community at its 2015 Life Sciences Celebration, which will be held Friday, October 30 at the Wyndham Garden Trenton from 8:00 to 10:00 a.m.

HINJ’s 2015 honorees will be:

  • The Honorable Bob Franks Public Service Award: Rep. Leonard Lance (R-7), Member, US House Energy and Commerce Committee
  • Research: Nils Lonberg, Ph.D., Senior Vice President, Oncology Discovery Biology, Bristol-Myers Squibb Company
  • Patient Advocacy: Deborah Brown, President and Chief Executive Officer, American Lung Association of the Mid-Atlantic

Continue reading

President’s Precision Medicine Initiative Advances; NIH Unveils Framework

Precision Medicine 4Bethesda, MD, September 18, 2015 ― The National Institutes of Health Advisory Committee to the Director (ACD) yesterday presented to NIH Director Francis S. Collins, M.D., Ph.D., a detailed design framework for building a national research participant group, called a cohort, of 1 million or more Americans to expand our knowledge and practice of precision medicine.

Dr. Collins embraced the design recommendations made by the ACD, noting the need to remain nimble and adaptable as the Initiative progresses.  He also thanked the Committee for their recommendations on policy issues and welcomed the opportunity to review them.

NIH plans to move quickly to build the infrastructure so that participants can begin enrolling in the cohort in 2016, with a goal of enrolling at least 1 million participants in three to four years. Continue reading